FTC Urged To Investigate AbbVie’s IP Strategy On Humira

US Representatives Suggest Biosimilar Adalimumab Competition Delayed From 2017 To 2023

 
• By David Wallace
  
Hourglass Delay Stop Time
The FTC has been asked to investigate AbbVie over delays to Humira biosimilars • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products